The clinical scope of glucagon-like peptide-1 receptor agonists is broadening rapidly as late-stage trials demonstrate efficacy across multiple systemic inflammatory conditions.
Cardiovascular Outcomes
Data from recent longitudinal studies indicate a 20% reduction in major adverse cardiovascular events among high-risk patients, triggering revised coverage guidelines by health insurers.
Production Constraints
Despite expanded manufacturing facilities, active pharmaceutical ingredient supply bottlenecks continue to restrict global market availability for maintenance doses.